AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01681316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
Study NCT01681316 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
Study NCT01681316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine-sertraline combination
Description: the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only olanzapine
Description: the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone-sertraline combination
Description: the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only risperidone
Description: the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone-sertraline combination
Description: the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only paliperidone
Description: the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone-sertraline combination
Description: the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
Study NCT04076371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: only ziprasidone
Description: the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
Study NCT02697565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Caregivers- Healthy Children Toolkit
Description: The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
Study NCT02697565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safety Curriculum
Description: Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
Study NCT03572361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-MOMMO
Description: Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
Study NCT03968250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Treating Fatigue
Description: The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed.
Study NCT00597506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
Study NCT00597506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg Everolimus(RAD001) daily by mouth, days 1-28
Study NCT04624776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
Study NCT04624776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
Study NCT02893904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Description: Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
Study NCT02893904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Description: Steady state effect site concentrations of remifentanil administrated to all patients.
Study NCT00525902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg delivered every 2 weeks by subcutaneous injection
Study NCT02747849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
Study NCT02747849 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
Study NCT04100915 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT01549041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg daily in the evening
Description: The total daily dose of Asenapine will be given once daily in the evening
Study NCT01549041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asenapine 5 mg twice daily
Description: Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
Study NCT01570634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Aluminosilicate Anti-Diarrheal (CASAD)
Description: CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
Study NCT02947542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One-catheter concept
Description: Coronary angiography will be performed using the one-catheter concept.
Study NCT02947542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard catheter
Description: Coronary angiography will be performed using a standard catheter.
Study NCT03005457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hemiparesis Therapy with VR
Description: An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
Study NCT04308915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-based cognitive training
Description: A suite of 5 games is presented to the participants for training working memory
Study NCT01594398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: 10 mg, po, q14 days, until progression or intolerable toxicity
Study NCT01594398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
Study NCT01594398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
Study NCT00719914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide
Description: Intra-coronary injection, weight based, of eptifibatide.
Study NCT00719914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide
Description: Intra-coronary injection, based on weight, of eptifibatide
Study NCT00719914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Intra-coronary injection, weight based, of normal saline.
Study NCT03603977 — intervention group
Intervention type: DRUG
Intervention: Lpv/r+3TC
Description: It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
Study NCT03844594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide Injection
Description: Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
Study NCT02356510 — intervention group
Intervention type: PROCEDURE
Intervention: Primary PCI
Study NCT00727090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
Study NCT04492072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intervention
Study NCT04492072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Control
Study NCT02712021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lycra suit and physiotherapy treatment
Description: Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
Study NCT02712021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: All the children will be involved in regular physiotherapy treatment (2-3/week).
Study NCT03457805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prostatic Artery Embolization
Description: PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)
Study NCT00830102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: * Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
Study NCT01766414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-esterase inhibitor
Description: intravenously
Study NCT01766414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: intravenously
Study NCT01766414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: intravenously
Study NCT01692132 — intervention group
Intervention type: DRUG
Intervention: Prucalopride
Description: Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
Study NCT03703843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTUS MONO
Description: Temporarily implant and activation of the medical device
Study NCT01560585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
Study NCT03121040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vespa amino acid mixture
Description: 17 kinds of amino acids mixture in specific proportion
Study NCT03664453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone
Description: Omaveloxolone 50 mg capsules
Study NCT04972539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51 Tab.
Description: Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
Study NCT01252862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of two iStents through a small temporal clear corneal incision
Study NCT01085136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator´s choice of chemotherapy
Description: BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Study NCT01085136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Study NCT03981965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity as described previously.
Study NCT03981965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity as described previously.
Study NCT04318639 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepazil
Description: Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice.
Study NCT04972539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R1 Tab. and A51R2 Tab.
Description: Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
Study NCT03518970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Description: The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers.
Study NCT02482064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexible resin
Description: This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
Study NCT02557373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
Study NCT02557373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Bran + Vitamin A
Description: 100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
Study NCT03702712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Relaxation
Description: This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
Study NCT03702712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Only
Description: This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
Study NCT03702712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Only
Description: This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
Study NCT01474421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Description: Patients will receive AQW051 in a high dose once daily orally for 28 days.
Study NCT01474421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051
Description: Patients will receive AQW051 in a low dose once daily orally for 28 days.
Study NCT01625689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL LAIV (live, trivalent seasonal influenza vaccine)
Description: Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
Study NCT01625689 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
Study NCT01429064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201
Description: ODM-201 administered orally daily
Study NCT04447495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: iAMP test
Description: The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.